Literature DB >> 8584112

Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary.

R Göke1, P J Larsen, J D Mikkelsen, S P Sheikh.   

Abstract

Glucagon-like peptide-1 (GLP-1) immunoreactivity has been found in autonomic and neuroendocrine brain regions, whereas only limited data are available regarding the characterization and localization of brain GLP-1 receptors. In the present study, using quantitative in vitro autoradiography, a high density of specific binding sites for GLP-1 was characterized on sections of the posterior pituitary lobe of the rat. Low specific binding of radiolabeled GLP-1 was found in the anterior lobe and no specific binding in the intermediate lobe. To examine the specificity of GLP-1 binding sites, sections of the posterior lobe were incubated with radiolabeled GLP-1 in the presence of various peptides. Radiolabeled [Tyr39]exendin-4, a specific GLP-1 agonist, bound to these receptor sites with the same affinity as GLP-1, while glucagon and vasoactive intestinal peptide (VIP) were unable to displace 125I-GLP-1. Both unlabeled exendin-4 and GLP-1 inhibited this binding with equally high affinity. Using 125I-[Tyr39]exendin-4 as radiolabel, the concentration of biding sites was found to be 7.8 +/- 0.4 fmol/mg tissue. Further analysis of the binding data from experiments with tissue slices revealed the presence of high and low affinity binding sites. In experiments with unlabeled [Tyr39]exendin-4, the KdS were 6.2 +/- 1.4 x 10(-12) and 9.3 +/- 1.5 x 10(-10) M, respectively, and in experiments with unlabeled GLP-1, 3.4 +/- 1.8 x 10(-12) and 5.9 +/- 1.5 x 10(-10) M, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584112     DOI: 10.1159/000126997

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  21 in total

1.  Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

Authors:  Claude Knauf; Patrice D Cani; Christophe Perrin; Miguel A Iglesias; Jean François Maury; Elodie Bernard; Fadilha Benhamed; Thierry Grémeaux; Daniel J Drucker; C Ronald Kahn; Jean Girard; Jean François Tanti; Nathalie M Delzenne; Catherine Postic; Rémy Burcelin
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice.

Authors:  David Tweedie; Lital Rachmany; Vardit Rubovitch; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Evelyn Perez; Jonathan Miller; Barry J Hoffer; Nigel H Greig; Chaim G Pick
Journal:  Exp Neurol       Date:  2012-10-08       Impact factor: 5.330

Review 3.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 4.  The gut and food intake: an update for surgeons.

Authors:  E Näslund; P M Hellström; J G Kral
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

5.  Characterization and distribution of prolactin releasing peptide (PrRP) binding sites in the rat--evidence for a novel binding site subtype in cardiac and skeletal muscle.

Authors:  F Satoh; D M Smith; J V Gardiner; M Mahmoodi; K G Murphy; M A Ghatei; S R Bloom
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 6.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Interspecies modeling and prediction of human exenatide pharmacokinetics.

Authors:  Ting Chen; Donald E Mager; Leonid Kagan
Journal:  Pharm Res       Date:  2012-11-15       Impact factor: 4.200

9.  Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction.

Authors:  Subhas C Biswas; Jean Buteau; Lloyd A Greene
Journal:  Neurochem Res       Date:  2008-03-20       Impact factor: 3.996

10.  Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.

Authors:  Jason G Barrera; David A D'Alessio; Daniel J Drucker; Stephen C Woods; Randy J Seeley
Journal:  Diabetes       Date:  2009-09-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.